#VELA investee #CDT Conduit Pharmaceuticals – Announces Opening of Prime Laboratory Space in Europe’s Leading Life Sciences Hub March 13, 2024 – Posted in: Vela Technologies Plc (VELA)

SAN DIEGO and LONDON, March 11, 2024 (GLOBE NEWSWIRE) — Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit Pharmaceuticals” or “Conduit”) today announced the opening of cutting-edge laboratory space in Cambridge, United Kingdom, a global centre for research and development for companies at the forefront of life science innovation. This strategic acquisition marks a pivotal milestone for Conduit, positioning the Company for portfolio expansion, enhanced development capabilities, and growth of a robust intellectual property portfolio. The laboratory…

Continue reading

#VELA Vela Technologies PLC – Interim Results December 22, 2023 – Posted in: Blog, Vela Technologies Plc (VELA)

Vela Technologies plc (AIM: VELA), an AIM-quoted investing company focused on early stage and pre-IPO disruptive technology investments, is pleased to announce its interim results for the six months ended 30 September 2023. Overview The last six months have continued to be challenging for capital markets with political unrest continuing both at home and abroad, the continuing war in Ukraine and rising inflation and interest rates continue to be factors impacting the small-cap marketplace in…

Continue reading

#VELA Vela Technologies PLC – Further update re. Economic Interest in AZD1656 September 8, 2023 – Posted in: Uncategorized

Further to the Company’s announcements on 15 August 2023 and 7 September 2023, the Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, notes that Murphy Canyon Acquisition Corp. (NASDAQ: MURF) (“Murphy”) announced yesterday that the special meeting of stockholders to approve, amongst other things, its initial business combination with Conduit Pharmaceuticals Limited has been postponed further and will now be held on 20 September 2023.  …

Continue reading